Target Validation Information
TTD ID	T20178
Target Name	Tumor necrosis factor (TNF)
Type of Target	Successful
Drug Potency against Target	Infliximab	Drug Info	IC50 = 37ng = ml	[5]
	Lenalidomide	Drug Info	IC50 = 5000 nM	[4]
	Pentoxifylline	Drug Info	IC50 = 100000 nM	[7]
	Pirenzepine	Drug Info	IC50 = 30.7 ug/ml	[3]
	Thalidomide	Drug Info	IC50 = 194000 nM
	AN0128	Drug Info	Ki = 40.0 nM	[6]
	Pirfenidone	Drug Info	IC50 = 30.7 ug/ml	[3]
	IK-862	Drug Info	IC50 = 0.35 nM	[2]
	PKF-241-466	Drug Info	IC50 = 269 nM	[1]
	PKF-242-484	Drug Info	IC50 = 48 nM	[1]
References
REF 1	Beta-aryl-succinic acid hydroxamates as dual inhibitors of matrix metalloproteinases and tumor necrosis factor alpha converting enzyme. J Med Chem. 2002 May 23;45(11):2289-93.
REF 2	Discovery of gamma-lactam hydroxamic acids as selective inhibitors of tumor necrosis factor alpha converting enzyme: design, synthesis, and structu... J Med Chem. 2002 Nov 7;45(23):4954-7.
REF 3	Inhibition of experimental acute pulmonary inflammation by pirfenidone. Pulm Pharmacol Ther. 2003;16(4):207-14.
REF 4	Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615.HCl). Blood. 2007 Feb 15;109(4):1669-77.
REF 5	Dominant-negative inhibitors of soluble TNF attenuate experimental arthritis without suppressing innate immunity to infection. J Immunol. 2007 Aug 1;179(3):1872-83.
REF 6	Dopamine D5 receptors: a challenge to medicinal chemists. Mini Rev Med Chem. 2008 Sep;8(10):976-95.
REF 7	Beneficial effects of the phosphodiesterase inhibitors BRL 61063, pentoxifylline, and rolipram in a murine model of endotoxin shock. Circ Shock. 1994 Dec;44(4):188-95.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.